Brand Name :
Krazati
Synonyms :
adagrasib
Class :
Antineoplastics, KRAS Inhibitors
Dosage forms & Strengths:
Adult:
Tablet
200 mg
600
mg
Orally
twice a day
Continue until the illness progresses or intolerable toxicity occurs.
Safety and efficacy are not seen in pediatrics
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may enhance the concentration of serum when combined with adagrasib
may increase the serum concentration of each other when combined
may increase the QTc prolonging effect
may increase the serum concentration of CYP2C9 Substrates
may decrease the therapeutic effect when combined with lenograstim
may decrease the therapeutic effect when combined with lipegfilgrastim
may have an increasingly adverse effect when combined with antineoplastic agents
may enhance the concentration of serum when combined with adagrasib
may increase the QTc-prolonging effect of QT-prolonging CYP3A4 Inhibitors
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
it may enhance the qtc interval when combined with lofexidine
may decrease the serum concentration of CYP3A4 Inducers
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
ximelagatran (investigational)
The combination of adagrasib may lead to a reduced metabolism of ximelagatran
Combining levobetaxolol and adagrasib can diminish levobetaxolol’s metabolism
When adagrasib and levobupivacaine are combined, the risk or seriousness of methemoglobinemia could rise
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
>10%:
Diarrhea
Nausea
Decreased lymphocytes
Fatigue
Vomiting
Increased AST
Decreased sodium
Decreased hemoglobin
Increased creatinine
Decreased albumin
Increased ALT
Pneumonia
Dizziness
Constipation
Abdominal pain
1-10%:
Hepatoxicity
Dyspnea
Decreased hemoglobin
Decreased sodium
Fatigue
Musculoskeletal pain
Renal impairment
Prolonged QT
Increased AST
Increased ALT
Nausea
Decreased appetite
Decreased potassium
Increased lipase
<1%:
Diarrhea
Vomiting
Dizziness
Cough
Decreased albumin
Adagrasib is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
No data is available regarding the use of the drug in the pregnant females.
Breastfeeding warnings:
No data is available regarding the excretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: adagrasib
Pronounced: ada-gras-ib
Why do we use adagrasib?
Adagrasib is an antineoplastic agent. It is used to treat non-small lung cancer.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
